Sign in
SuspendedNo phase

Abnormal Vascular, Metabolic, and Neural Function During Exercise in Heart Failure With Preserved Ejection Fraction

Key facts

Who runs it
University of Texas Southwestern Medical Center
Where
Dallas, United StatesSee the site
Trial code
Status
Suspended
People taking part
22 people, planned
Started
1 Feb 2018
Expected to end
1 Mar 2027
Type of study
Interventional
Treatments tested
  • Exercise training
Record updated
22 July 2026
Why it stopped
The first major aim of this project has been accomplished. This project is temporarily on hold while other projects are prioritized.

Who can take part

Age
65 years to 85 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 18 criteriaShow less

Other criteria

  • All subjects will be >65 years of age. The controls will be screened carefully for hypertension and cardiac disease, including structural heart and hemodynamically significant obstructive coronary disease, using a history, physical examination, and resting and post-exercise transthoracic echocardiograms. Additional exclusion criteria for this group will include valvular heart disease, atrial flutter/ fibrillation, renal insufficiency, chronic lung disease, regular cigarette smoking within the past 10 years, and cardiovascular medication. Subjects demonstrating greater than moderate levels of activity > 2 days per week will not be allowed to participate, as chronic high levels of physical activity could potentially impact the primary outcome variables
  • HFpEF Inclusion Criteria:
  • Patients will be > 65 years old
  • We will use a modification of the European Guidelines for the diagnosis of HFpEF to select the patient population
  • The key components of these guidelines include:; signs and symptoms of heart failure; b) an ejection fraction > 0.50; and; c) objective evidence of diastolic dysfunction. To satisfy the first criteria, we will use the Framingham criteria (dyspnea, orthopnea, PND, edema); however we will require objective evidence of congestion including
  • chest X-ray,
  • elevated BNP,
  • or elevated PCWP (pulmonary capillary wedge pressure) or
  • LVEDP (left ventricular end-diastolic pressure) > 16 mmHg; for the second, we will accept echo, nuclear or catheter documentation; and for
  • we will require a depressed tissue Doppler mitral annular velocity < 7.5 cm/s along with PCWP > 16 mmHg if available; HFpEF Exclusion Criteria:
  • underlying valvular or congenital heart disease
  • restrictive or infiltrative cardiomyopathy
  • acute myocarditis
  • NYHA Class IV CHF, or CHF that cannot be stabilized on medical therapy
  • other condition that would limit the patient's ability to complete the protocol
  • manifest ischemic heart disease
  • Patients with CABG or previous history of atrial fibrillation will be allowed to participate, though for safety reasons, patients on Coumadin will be excluded
  • All patients must be in sinus rhythm without a left bundle branch block at the time of study, and be off beta blockers or non-dihydropyridine Ca++ blockers for at least 5 half-lives. β blockers will be weaned over 3-5 days and additional doses of vasodilators added to control blood pressure if necessary. Drugs that affect the renin-angiotensin-aldosterone system and diuretics will be maintained

Where in United States

  • The Institute for Exercise and Environmental MedicineDallas, United States

About the trial

What the trial wants to find out

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of the heart failure population in the United States. The primary chronic symptom in patients with HFpEF is severe exercise intolerance quantified as reduced peak oxygen uptake during whole body exercise (peak V̇O2). To date, studies have focused almost exclusively on central cardiac limitations of peak V̇O2 in HFpEF. However, in stark contrast to heart failure with reduced ejection fraction (HFrEF), drug therapies targeting central limitations have invariably failed to improve peak V̇O2, quality of life, or survival in HFpEF. Emerging evidence from our lab suggests reduced skeletal muscle oxidative capacity may contribute to exercise intolerance in HFpEF patients. However, the mechanisms responsible for peripheral metabolic inefficiency remain unclear. Reduced blood flow (oxygen delivery), and slowed oxygen uptake kinetics (O2 utilization) may both contribute to reduced peripheral oxidative capacity. Importantly, reduced oxidative capacity may result in increased production of metabolites known to activate muscle afferent nerves and stimulate reflex increases in muscle sympathetic (vasoconstrictor) nervous system activity (MSNA). However, to date there have been no studies specifically investigating the contribution of peripheral metabolic and neural impairments to reduced exercise capacity in HFpEF. The overall aim of this proposal will be 1) to identify impairments in peripheral vascular, metabolic, and sympathetic neural function and 2) to assess the ability of small muscle mass (knee extensor, KE) training, specifically targeting these peripheral skeletal muscle deficiencies, to improve aerobic capacity and exercise tolerance in HFpEF.

Read full original descriptionShow less

GLOBAL HYPOTHESIS 1: HFpEF patients will demonstrate reduced skeletal muscle oxygen delivery, slowed oxygen uptake kinetics, and elevated resting and metaboreflex mediated MSNA.

Hypothesis 1.1: The vasodilatory response to knee extensor exercise will be impaired in HFpEF patients.

Specific Aim 1.1: To measure the immediate rapid onset vasodilatory response to muscle contraction, as well as the dynamic onset, and steady state vasodilatory responses to dynamic KE exercise.

Hypothesis 1.2: Skeletal muscle oxygen uptake kinetics will be slowed in HFpEF.

Specific Aim 1.2: To measure pulmonary oxygen uptake kinetics during isolated KE exercise in order to isolate peripheral impairments in metabolic function independent of any central impairment.

Hypothesis 1.3: HFpEF patients will demonstrate elevated MSNA at rest, and exaggerated metaboreflex sensitivity during exercise.

Specific Aim 1.3: To test this hypothesis the investigators will measure MSNA from the peroneal nerve at rest, and during post exercise ischemia to directly assess metaboreflex sensitivity in HFpEF.

GLOBAL HYPOTHESIS 2: Isolating peripheral adaptations to exercise training using single KE exercise training will improve peripheral vascular, metabolic, and neural function and result in greater functional capacity in HFpEF.

Hypothesis 2.1: Isolated KE exercise training will improve the vasodilatory response to exercise, speed oxygen uptake kinetics, and reduce MSNA at rest HFpEF.

Specific Aim 2.1: The assessments of vascular, metabolic, and neural function proposed in hypothesis 1 will be repeated after completing 8 weeks of single KE exercise training.

Hypothesis 2.2: Single KE exercise training will improve whole body exercise tolerance, peak V̇O2, and functional capacity in HFpEF.

Specific Aim 2.2: To test this hypothesis the investigators will measure maximal single KE work rate, V̇O2 kinetics and peak V̇O2 during cycle exercise, as well as distance covered in the six minute walk test.

The group in the trial

  • Exercise trainingTreatment being tested

    8 Weeks exercise training 3x per week 30-40 minutes per session

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
22 July 2026